 Home > Biochemistry News > Biotechnology News > Keytruda receives FDA approval for the first time to treat early-stage kidney cancer to reduce the risk of recurrence by 32%

Keytruda receives FDA approval for the first time to treat early-stage kidney cancer to reduce the risk of recurrence by 32%

 Last Update: 2021-12-02
 Source: Internet
 Author: User

Tags

refrigerators become common

which following carboxyl group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Merck & Co.

Renal cell carcinoma is the most common type of kidney cancer.

This approval is based on the results of a pivotal Phase 3 clinical trial

In addition, the data released at this year's ESMO conference show that Keytruda also shows a good trend in reducing the risk of death in patients, reducing the risk of death in patients by 46% compared with placebo

▲The results of Keytruda in the pivotal Phase 3 clinical trial (Image source: Merck official website)

"The adjuvant treatment options for early renal cell carcinoma are limited, and Keytruda's approval provides a new treatment option for patients with a higher risk of recurrence

The use of immunotherapy to treat early-stage cancer patients, reduce disease recurrence, and improve cancer cure rate is the research direction of many pharmaceutical companies

We look forward to the combination of the application of immunotherapy in early cancer and more effective early cancer screening methods, so that more patients can be diagnosed earlier, receive effective treatment earlier, and embark on the road to cure

Reference materials:

[1] FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery.

[2] Merck Oncology Overview.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.